Chloroquine as a Modulator of T Cell Immune Activation

NCT ID: NCT02004314

Last Updated: 2013-12-09

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 19 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2009-10-31
• Study Completion Date: 2012-03-31

Brief Summary

This study will evaluate the effect of chloroquine in individuals infected with HIV. Researchers will aim to determine if chloroquine treatment in participants whose viral loads are suppressed on combination antiretroviral therapy (ART), results in improved immune activation and CD4 cell recovery.

The study will recruit 20 individuals and will last approximately 44 weeks. Eligible participants will receive an oral dose of chloroquine (250 mg) once daily from week 8 through week 32. All participants will be asked to have rectal biopsy samples (week 0 and week 32) to study T cell immune activation in the mucosa rectal site.

Detailed Description

Clinical data has identified chloroquine as a potential modulator of immune activation. The study's dose of chloroquine is the same as the dose recommended for patients having autoimmune diseases. In these autoimmune cases, a daily dose of chloroquine at 250 mg for 12 weeks has shown improvement in symptoms and decreases in inflammatory cytokines synthesis and a reduction in TLR -mediated immune activation. Study findings could help provide information about where and under what circumstances chloroquine treatment may reduce T cell activation and help restore circulating CD4 T cells.

Conditions

HIV

Keywords

Chloroquine; T cell immune activation; CD4 recovery; HIV

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Chloroquine

This will be a single arm, pilot study with each subject as his/her own control. The study will last 44 weeks, with 8 weeks observation period on ART alone to assess stability of activated CD8CD38 T cells, followed by 24 weeks chloroquine treatment with ART and a 12-week follow-up period on ART alone. Twenty ART treated patients will be recruited. To maximize chances of demonstrating a treatment effect, the chloroquine will be administrated for 24 weeks.

Group Type: OTHER

Chloroquine

Intervention Type: DRUG

Interventions

Chloroquine

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Documented HIV infection by Western Blot, EIA assays or viral load assay.
• Aged between 18 and 65 years.
• Viral load less than 50 copies per ml for at least the previous 36 weeks.
• CD4 cell count less than or equal to 350 cells per litre.
• On stable ART
• Vital signs, physical examination and laboratory results do not exhibit evidence diseases such as advanced cirrhosis or advanced liver
• Karnofsky performance status greater than or equal to 80 per cent.
• Participant does not require and agrees not to take, for the duration of the study, any medication that is contraindicated with chloroquine.
• Able to give informed consent.

Exclusion Criteria

• Active AIDS events in the last 3 months
• Co-infection with active hepatitis B or C virus.
• Current use or use within four weeks prior to the baseline visit, of cytotoxic agents, systemic corticosteroids or any immuno-modulatory agents.
• Current use within four weeks prior to the chloroquine therapy the following medications: methadone, chlorpromazine, cimetidine, cyclosporin, methotrexate and penicillanime.
• Psychiatric or cognitive disturbance or illness that could preclude compliance with the study.
• Patient with clinically significant hemophilia and Von-Willebrand disease and any severe bleeding disorder.
• Experimental HIV immune based therapy within 6 months of screening visit.
• Allergic reaction to chloroquine.
• A history of retinitis or any retinal problem.
• Subjects with G6PD deficiency, porphyria, psoriasis, cirrhosis, hearing deficiency (including tinnitus), myopathy and cardiomyopathy.
• Pregnant and breast-feeding women.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

CIHR Canadian HIV Trials Network

NETWORK

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Jean-Pierre Routy, MD.

Role: PRINCIPAL_INVESTIGATOR

McGill University Health Centre/Research Institute of the McGill University Health Centre

Locations

Montreal Chest Institute, McGill University Health Centre

Montreal, Quebec, Canada

Countries

Canada

References

Routy JP, Angel JB, Patel M, Kanagaratham C, Radzioch D, Kema I, Gilmore N, Ancuta P, Singer J, Jenabian MA. Assessment of chloroquine as a modulator of immune activation to improve CD4 recovery in immune nonresponding HIV-infected patients receiving antiretroviral therapy. HIV Med. 2015 Jan;16(1):48-56. doi: 10.1111/hiv.12171. Epub 2014 Jun 2.

Reference Type: DERIVED

PMID: 24889179 (View on PubMed)

Other Identifiers

CTN 246

Identifier Type: -

Identifier Source: org_study_id